SIRT1 and myocardial infarction: A study newly published in August 2024 focused on how dapagliflozin mitigates myocardial cell injury induced by acute myocardial infarction by increasing the sirtuin family (SIRT1/SIRT3) and cascade signaling, finding that dapagliflozin increases the gene and protein expression of SIRT1, SIRT3, and SIRT6, and antagonizes the hypoxia-induced downregulation of genes such as ESRRA, EPAS1, and AGTRAP (Lin et al., 2024).